Delayed union or nonunion of bone fragments occurs in about 510% of patients with bone fracture (Gomez-Barrena et al

Delayed union or nonunion of bone fragments occurs in about 510% of patients with bone fracture (Gomez-Barrena et al., 2015). development of endochondral and membranous bones; and the contributions of VEGF to bone healing during different phases of bone repair. Finally, we discuss contributions of altered VEGF function in inherited disorders with bone defects as part of their phenotypes, and we speculate Pirfenidone on what will be required before therapeutic strategies based on VEGF modulation can be developed for clinical use to treat patients with bone growth disorders and/or compromised bone repair. == Introduction == Bones are highly vascularized organs. Blood vessel cells and bone cells communicate in many ways during development, fracture healing and bone regeneration (Clarkin and Gerstenfeld, 2013, Carano and Filvaroff, 2003). For example , osteoblasts are major sources of angiogenic factors, including VEGF, that stimulates angiogenesis (Wang et al., 2007, Hu and Olsen, 2016), and blood vessels provide oxygen, nutrients and minerals as well as secreted factors that are necessary for bone formation (Kusumbe et al., 2014). Within the bone marrow space, F3 stem cell niches contain osteoblastic progenitor cells residing around blood vessels (Worthley et al., 2015), and periosteal osteoblast precursors, in a pericyte-like manner, migrate into bone-forming sites along with invading blood vessels during development and fracture healing (Maes et al., 2010). Vascular morphogenesis also provides a spatial and functional template for skeletal morphogenesis in development and postnatal growth. In early development, generation of hypoxic regions by loss of blood vessels is an essential step that allows mesenchymal condensations and cartilage models of endochondral bones to form (Amarilio et al., 2007); in Pirfenidone turn, the condensations produce VEGF that regulates vascular morphogenesis in the tissues surrounding the cartilage-forming regions (Eshkar-Oren et al., 2009). During postnatal growth and homeostasis, lamellae of cortical bone are patterned around blood vessels and nerves in Haversian canals (Bogonatov and Gonchar-Zaikina, 1976), and metaphyseal trabecular bone is patterned around the vasculature that invades hypertrophic cartilage in developing and postnatal growth plates (Maes, 2013). Thus, osteogenesis and angiogenesis are coupled processes (Clarkin and Gerstenfeld, 2013; Ramasamy et al., 2015). Since vascular control is essential for bone development and repair, impairment of this control affects the skeletal system. Deficiencies in vascular supply can lead to osteonecrosis (Childs, 2005), often involving mandibles or the ends of long bones. Reduction in the number of capillaries in trabecular bone is associated with decreased bone formation and bone mass in osteoporosis (Burkhardt et al., 1987). Lack of blood supply after bone injury is considered to be the major reason for compromised fracture healing, affecting about 10% of patients with bone fracture (Gomez-Barrena et al., 2015, Bishop et al., 2012). VEGF is one of the most important regulators of vascular development and angiogenesis (Coultas et al., 2005, Hoeben et al., 2004), and it is therefore also critical for bone health. In addition , VEGF has direct effects on osteoblast and osteoclast differentiation and function. In this review, we summarize the roles of VEGF in bone growth and repair, and we speculate on how VEGF-based therapeutic strategies may improve bone health. == VEGF == The VEGF family includes at least 6 members: VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGF-E and placental growth factor (Cross et al., 2003, Ferrara et Pirfenidone al., 2003). VEGF-A, usually referred to as VEGF, was discovered first and plays critical roles in angiogenesis and promotion of vessel permeability (Ferrara et al., 2003). Through the utilization of two transcriptional start sites and alternative splicing, the two VEGF-A primary transcripts generate several mRNAs (Arcondguy et al., 2013). Consequently, several protein isoforms containing different numbers of amino acid residues exist. These include Pirfenidone VEGF121, freely diffusing through the extracellular matrix (ECM) because it lacks heparin-binding sites, VEGF189 and VEGF206, both containing two heparin-binding sites and therefore sequestered in the ECM, and VEGF165, the most abundant isoform containing one heparin-binding site (Conn et al., 1990, Pepper et al., 1994). A variety of cell types within or around blood vessels express VEGF, such.